Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
- 1 February 2009
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 136 (2), 441-450.e1
- https://doi.org/10.1053/j.gastro.2008.10.051
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Meta‐analysis: factors predicting post‐operative recurrence with placebo therapy in patients with Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2008
- Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgeryGut, 2005
- A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study GroupGastroenterology, 1997
- Prognostic factors for postoperative recurrence of Crohn's diseaseDiseases of the Colon & Rectum, 1996
- Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's diseaseGastroenterology, 1995
- Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's diseaseGastroenterology, 1995
- Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms.Gut, 1992
- Primary and Recurrent Crohnʼs DiseaseAnnals of Surgery, 1991
- Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms.Gut, 1988
- The Long-term Prophylactic Effect of Salazosulfapyridine (SalazopyrinR) in Primarily Resected Patients with Crohn's DiseaseScandinavian Journal of Gastroenterology, 1978